Close the gap in precision oncology.
Every eligible patient.
Every next step.
CancerIQ helps oncology teams identify patients eligible for biomarker and molecular tumor testing, liquid biopsy, and MRD, surface guideline-based recommendations, and understand what comes next — from diagnosis through survivorship.
The science is ready. The workflow isn't always.
Across screening, risk, treatment, and survivorship, CancerIQ connects more patients to the tests that guide their care — and helps ensure those tests are completed, not just ordered.
of newly diagnosed cancer patients undergo recommended germline testing4
Kurian AW, et al. Germline Genetic Testing After Cancer Diagnosis. JAMA. 2023;330(1):43–51.
Eligible patients with advanced cancer actually receive biomarker testing¹
JAMA Network Open, 2025 (via Oncology Nursing Society)
Tested patients still don't receive the appropriate targeted treatment²
JCO Precision Oncology
The same diagnosis. A different outcome.
Three patients, three tests that could have changed their care. Flip each card to see the difference CancerIQ makes.
OlympiA (NEJM 2021; SABCS 2024) · Kurian, JAMA 2023 · CIRCULATE-Japan GALAXY (Nat Med 2023). MRD is framed as an earlier signal that prompts evaluation, not a standalone treatment mandate.
Female, 44
Newly diagnosed triple-negative breast cancer
- Met NCCN criteria for germline testing at diagnosis — not tested
- Treatment planned on tumor features alone
No adjuvant PARP inhibitor offered; risk-reducing surgery never discussed
Improve the outcome with CancerIQ
Completed at intake
BRCA1 identified before surgery and before the adjuvant decision — enabling a risk-informed surgical discussion, adjuvant PARP therapy, and family cascade testing.
Male, 58 · never-smoker
Newly diagnosed metastatic lung adenocarcinoma
- Systemic therapy started before biomarker/NGS results returned
- Driver mutation status still unknown at first-line decision
Immunotherapy given instead of targeted therapy — severe immune-related toxicity
Improve the outcome with CancerIQ
In motion before first-line
NGS returned an EGFR exon 19 deletion before treatment began, redirecting care to guideline-concordant first-line targeted therapy.
Male, 61
Resected stage III colon cancer
- Standard imaging and CEA surveillance only; MRD not offered
- No molecular signal tracked after adjuvant therapy
Recurrence detected late on imaging, in a narrower treatment window
Improve the outcome with CancerIQ
Offered at survivorship checkout
Serial ctDNA testing ran alongside imaging, surfacing a molecular signal of recurrence earlier and prompting timely workup.
How CancerIQ closes the gap in precision oncology.
- Screen CancerIQ automates identification of biomarker-, liquid biopsy-, and MRD-eligible patients across your population, flagging them for testing.
- Educate Patients and care teams get clear, guideline-aligned context on what a result means and what the next step is.
- Diagnose CancerIQ tracks testing status inside the EHR — from order to result — so a pending biomarker result doesn't stall a treatment decision.
- Manage Survivors stay connected to MRD and recurrence-surveillance schedules, with no patient falling through the cracks between appointments.
- Measure Clear reporting on testing completion, turnaround, and downstream outcomes for program leaders.
Ready to see CancerIQ for precision oncology?
Join us for a quick, no-pressure look at how CancerIQ identifies patients eligible for biomarker testing, liquid biopsy, and MRD — and helps connect each result to a documented, guideline-aligned next step, complementing the tools your team already uses. Just 30 minutes, nothing to prepare on your end. Built around your program, not a generic demo.
Trusted by 60+ Health Systems Across 275+ Clinical Locations
CancerIQ connects eligible patients to the tests that guide their care — across screening, risk, treatment, and survivorship — inside the EHR your team already uses. That includes biomarker and molecular tumor testing, liquid biopsy, and MRD, working alongside our lab and diagnostic partners.
More on CancerIQ for Precision Oncology
What does CancerIQ do for precision oncology programs?
CancerIQ helps care teams identify patients who may be eligible for testing across screening, risk, treatment, and survivorship. For precision oncology, CancerIQ surfaces eligibility for biomarker and molecular tumor testing, liquid biopsy, and MRD testing, along with a guideline-based recommendation tier — Recommended, Consider, or Not applicable.
Is this the same as CancerIQ’s hereditary risk and genetics solution?
It builds on the same eligibility and recommendation framework CancerIQ uses for hereditary genetic testing, extended to patients in active treatment and survivorship. This allows organizations already using CancerIQ for cancer risk and genetics to support additional testing needs across the cancer care continuum.
What types of tests does CancerIQ support?
CancerIQ supports a growing range of precision oncology testing, including biomarker and molecular tumor testing, liquid biopsy, and MRD testing. Each test in the catalog includes guideline-sourced eligibility logic to help care teams determine when testing may be appropriate.
CancerIQ works alongside laboratory and diagnostic partners rather than performing testing itself.
How does CancerIQ determine which tests may be appropriate for a patient?
CancerIQ evaluates relevant patient information against guideline-sourced eligibility criteria and surfaces a recommendation of Recommended, Consider, or Not applicable. This distinction is especially important in areas where evidence and guidelines are still evolving. When routine use is not currently recommended, CancerIQ reflects that nuance in the recommendation presented to the care team.
How does CancerIQ support MRD and recurrence surveillance?
CancerIQ incorporates guideline-sourced eligibility criteria and recurrence-testing intervals to help care teams identify patients for whom MRD testing may be appropriate and understand the applicable recommendation.
Does CancerIQ replace our EHR or existing oncology workflow tools?
No. CancerIQ is designed to work within your existing technology environment, including integrations with leading EHRs. It complements your existing infrastructure and oncology workflows rather than replacing them.
Does CancerIQ replace our lab or diagnostic partners?
No. CancerIQ works across laboratory and diagnostic partners. Its role is to identify patients who may be eligible for testing and surface the applicable guideline-based recommendation, while testing itself is performed by the diagnostic partner.
How is CancerIQ different from what a molecular pathology lab or NGS vendor provides?
Labs and NGS vendors perform testing and generate results. CancerIQ works upstream, helping care teams identify which patients may be eligible for testing and which guideline-based recommendation applies. This gives health systems a consistent approach across patients, tumor types, and diagnostic partners.
What does implementation look like?
Implementation depends on your EHR environment, existing testing workflows, and current CancerIQ footprint. We’ll work with your team to determine the right approach.
What does CancerIQ cost?
CancerIQ works with organizations of every size — from small and independent practices to enterprise health system partners — and pricing is scoped to your program rather than a flat rate. We'll work with you to figure out what makes sense based on your patient population, testing volume, and goals. The demo itself is always free, with no obligation.